Deuruxolitinib

Sun Pharma · CTP-543

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
3 active
18 in total
Targets
 

What this is

How it works
JAK1/JAK2 inhibitor
How it’s given
“Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg”In the company’s words, NCT07617597 on ClinicalTrials.gov
Tested for
Alopecia Areata (3 trials)
Main trialPhase 3
“This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.”In the company’s words, NCT07617597 on ClinicalTrials.gov
Other names
CTP-543 · Leqselvi

Other drugs for Alopecia Areata

All 16 drugs for Alopecia Areata

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials18

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Feb 2028 Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata
Phase 3Recruiting May 2028 Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Phase 2/3Active, not recruiting May 2027 Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Phase 3Completed 19 Apr 2022 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)
Phase 3Completed 8 Jun 2022 Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
Phase 3Completed 18 Jul 2024 European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Phase 2Completed 8 Jul 2019 Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
Phase 2Completed 21 Nov 2019 Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
Phase 2Completed 10 Apr 2020 Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
Phase 2Completed 16 May 2023 A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
Phase 1Completed 27 Mar 2021 Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult Subjects
Phase 1Completed 24 Jun 2021 Drug-drug Interaction Study of CTP-543 and Rifampin in Healthy Adult Subjects
Phase 1Completed 28 Jan 2022 A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers
Phase 1Completed 26 Jun 2022 Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers
Phase 1Completed 30 Jun 2022 Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects
Phase 1Completed 6 Aug 2022 Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects
Phase 1Completed 15 Sep 2022 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
Phase 1Completed 20 Oct 2022 Study to Assess the Effect of Renal Impairment on the Pharmacokinetics of CTP-543
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Deuruxolitinib

Following is part of Solo: you see every change to Deuruxolitinib the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in